UK-EU Northern Ireland Deal Reinstates ‘Single UK Market For Medicines’
Executive Summary
Under the landmark “Windsor Framework” agreed by the UK and the EU, medicines will take the “green lane” from Great Britain to Northern Ireland, while the UK regulator will have UK-wide responsibility for all drug approvals. In addition, the provisions of the EU Falsified Medicines Directive will no longer apply in Northern Ireland.
You may also be interested in...
UK Outlines Upcoming Application Rules For Generics
New legislation that will come into effect at the beginning of 2025 will change the originator products that UK generics manufacturers must refer to when applying to bring certain products to market.
UK Regulator Attempts To Demystify Upcoming Drug Approval Rules
New guidance from the MHRA covers the issuing of UK-wide approvals for all medicines from 2025, the conversion of Great Britain product licences to UK licences, and issues relating to the approval of generics and the use of reference and comparator products.
EU Wants ‘Written Guarantees’ From UK On New Medicine Rules
Numerous political and legislative procedures will be needed before new rules on the UK-wide approval of new medicines and their marketing in Northern Ireland can be implemented.